{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:17:47Z","timestamp":1720628267831},"reference-count":14,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3814,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-504x.2005.00423.x","type":"journal-article","created":{"date-parts":[[2005,3,23]],"date-time":"2005-03-23T10:27:06Z","timestamp":1111573626000},"page":"3-5","source":"Crossref","is-referenced-by-count":10,"special_numbering":"supplement s147","title":["Ezetimibe-induced hyperlipidaemia"],"prefix":"10.1155","volume":"59","author":[{"given":"E.","family":"Doherty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Lumb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Chik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Wierzbicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,23]]},"reference":[{"issue":"147","key":"10.1111\/j.1368-504X.2005.00423.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","article-title":"Ezetimibe","volume":"11","author":"Bays","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1111\/j.1368-504X.2005.00423.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1742-1241.2003.tb10582.x","article-title":"Ezetimibe: a new addition to lipid-lowering therapy","volume":"57","author":"Wierzbicki","year":"2003","journal-title":"Int J Clin Pract"},{"issue":"8","key":"10.1111\/j.1368-504X.2005.00423.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomised placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1368-504X.2005.00423.x-BIB4|cit4","article-title":"Efficacy of ezetimibe in patients with statin-resistant familial hypercholesterolaemia","author":"Wierzbicki","journal-title":"Curr Med Res Opin"},{"issue":"32","key":"10.1111\/j.1368-504X.2005.00423.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"33586","DOI":"10.1074\/jbc.M405817200","article-title":"Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis","volume":"279","author":"Davis","year":"2004","journal-title":"J Biol Chem"},{"issue":"5661","key":"10.1111\/j.1368-504X.2005.00423.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004 February 20","journal-title":"Science"},{"issue":"10","key":"10.1111\/j.1368-504X.2005.00423.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0400441101","article-title":"Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport","volume":"101","author":"Smart","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1111\/j.1368-504X.2005.00423.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1111\/j.1368-504X.2005.00423.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(01)00825-1","article-title":"The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys","volume":"415","author":"Van Heek","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1111\/j.1368-504X.2005.00423.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2001.26737","article-title":"The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs","volume":"50","author":"Davis","year":"2001","journal-title":"Metabolism"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-504X.2005.00423.x-BIB11|cit11","first-page":"S33","article-title":"Preclinical and clinical pharmacology of a new class of lipid management agents","volume":"8","author":"Rudel","year":"2002","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1111\/j.1368-504X.2005.00423.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-2275(20)41990-X","article-title":"Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia","volume":"32","author":"Elmberger","year":"1991","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1111\/j.1368-504X.2005.00423.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0939-4753(04)80033-4","article-title":"Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism","volume":"14","author":"O'Neill","year":"2004","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"10.1111\/j.1368-504X.2005.00423.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"Van Heek","year":"2000","journal-title":"Br J Pharmacol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-504X.2005.00423.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-504X.2005.00423.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T17:44:24Z","timestamp":1683049464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-504X.2005.00423.x"}},"subtitle":["ezetimibe-induced hyperlipidaemia"],"short-title":[],"issued":{"date-parts":[[2005,3,23]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1111\/j.1368-504x.2005.00423.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3,23]]}}}